DUBAI, UAE - - 28 January 2025 - AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place to work across the ...
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...